Vaccination in the setting of sexually transmitted infections consultation

Lanyu Sun, Service of Dermatology, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portuga Claúdia Brazão, Service of Dermatology, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portuga Dora Mancha, Service of Dermatology, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portuga Diogo de Sousa, Service of Dermatology, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal João Borges-Costa, Service of Dermatology, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte; Clínica Universitária de Dermatologia, Faculdade de Medicina da Universidade de Lisboa; Instituto de Higiene e Medicina Tropical, Universidade Nova de Lisboa, Lisbon, Portugal

Sexually transmitted infections (STIs) are a significant public health concern across the globe. Vaccines have played a crucial role in mitigating the burden of infectious diseases and are the most effective candidates for preventing STIs. Currently, vaccines for hepatitis A, hepatitis B virus (HBV), and human papillomavirus (HPV) are available. More recently, the smallpox vaccine was approved for Mpox (MPX) prevention. Ongoing research efforts are focused on developing vaccines for other STIs. This paper reviews the current indications for available vaccines for use in the context of STIs and discusses some of the vaccines currently being researched.

Palabras clave: Hepatitis A. Hepatitis B. Human papillomavirus. Mpox. Sexually transmitted infections. Vaccine.